VertiFlex Announces 200 Patients Enrolled in Superion(R) IDE Trial

SAN CLEMENTE, Calif.--(BUSINESS WIRE)--VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 200 patients have been enrolled in its pivotal IDE clinical trial of the Superion® Interspinous Spacer (ISS).

MORE ON THIS TOPIC